Biotechnology

Crescent Biopharma

Crescent Biopharma released FY2026 Q1 earnings on April 29 (EST), actual revenue USD 1.039 M (forecast USD 357.14 K), actual EPS USD -0.6994 (forecast USD -0.9457)

Crescent Biopharma released FY2025 Q4 earnings on February 26, 2026 (EST), actual revenue USD 10.84 M (forecast USD 7.5 M), actual EPS USD -3.3529 (forecast USD -2.5162)

Crescent Biopharma released FY2025 Annual Earnings on February 26 (EST), actual revenue USD 10.84 M (forecast USD 7.5 M), actual EPS USD -12.8149 (forecast USD -11.13)

Sichuan Kalen Biomedical's SKB105 Receives NMPA Clinical Trial Approval and Establishes Strategic Partnership

CoLon Biotech and Crescent Biopharma Enter into Collaboration for Oncology Drug Development

Crescent Biopharma and Kelun-Biotech Partner to Develop Novel Cancer Treatments

H.C. Wainwright Reiterates Buy Rating on Crescent Biopharma

Crescent Biopharma released FY2025 9 Months Earnings on November 6, 2025 EST, with actual revenue USD 0 and EPS USD -24.5846

Crescent Biopharma released FY2025 Q3 earnings on November 6, 2025, EST: Actual Revenue USD 0 (Forecast USD 0), Actual EPS USD -1.2663 (Forecast USD -1.352)

LifeSci Capital Analyst Maintains Buy Rating on Crescent Biopharma

Crescent Biopharma to Present Clinical Data of Dual-Antibody CR-001 at SITC Annual Meeting

Crescent Biopharma released FY2025 Q2 earnings on July 31 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -4.9272 (forecast USD -3.145)

Crescent Biopharma released FY2025 Semi-Annual Earnings on July 31 (EST) with actual revenue of USD 0 and EPS of USD -14.1137

Crescent Biopharma Submits Beneficial Ownership Statement to SEC

Crescent Biopharma Stock Breaks 200-Day Moving Average

FactSet Survey Analysts Rate Crescent Biopharma as Buy

Crescent Biopharma Submits Beneficial Ownership Statement

Crescent Biopharma released FY2025 Q1 earnings on May 14 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -18.3909 (forecast USD -3.64)

Crescent Biopharma released FY2024 Q1 earnings on May 14, 2025 (EST), with actual revenue USD 0 (forecast USD 0) and actual EPS USD -16.657 (forecast USD -16.5)

Crescent Biopharma released FY2023 Annual Earnings on February 13, 2025 (EST), with actual revenue of USD 10K (forecast USD 0) and actual EPS of USD -58.2538 (forecast USD -60.25)

NVIDIA

Alphabet

Alphabet - C

Apple

Microsoft

Amazon

Taiwan Semiconductor

Broadcom

Meta Platforms

Tesla

CBIO

Crescent Biopharma, Inc. announced on May 12, 2026, that its Board of Directors authorized the granting of options to acquire 129,075 shares to five non-executive employees as part of the 2025 Employment Inducement Incentive Award Plan. This decision, made on May 11, 2026, complies with Nasdaq Listing Rule 5635(c)(4) and is essential for the employees' acceptance of employment.

Unusual Whales

Nasdaq

Crescent Biopharma Announces Grants of Inducement Awards

Crescita Reports First Quarter 2026 Results | CRRTF Stock News

StockTitan

Crescita Reports First Quarter 2026 Results | CRRTF Stock News

Earnings Watch

Crescent Biopharma | 10-Q: FY2026 Q1 Revenue: USD 22.52 M

Crescent Biopharma | 8-K: FY2026 Q1 Revenue: USD 22.52 M

Stifel Nicolaus analyst Stephen Willey has reaffirmed a Buy rating on Crescent Biopharma (CBIO) with a price target of $30.00. Willey, who specializes in the Healthcare sector, has an average return of 8.8% and a 43.00% success rate on his stock recommendations. The consensus among analysts for Crescent Biopharma is a Strong Buy, with a price target consensus of $29.50.

Tip Ranks

Stifel Financial

Disc Medicine

Incyte

Insmed

STIFEL FINANCIAL CORP 6.125% DEP SHS REP 1/1000 NON CU PF SR C

Stifel Financial Pref Share SFB 5.2 10/15/47

STIFEL FINANCIAL CORP 6.25%NON CUM DEP SHS REP 1/1000TH SER B

STIFEL FINANCIAL CORP 4.50% DEP SHS REP 1/1000TH PREF SHS SR D

Stifel Nicolaus Keeps Their Buy Rating on Crescent Biopharma (CBIO)

CGEN

GBIO

SBIO

LABU

IBBQ

CGBIO has received FDA 510(k) clearance for its patient-specific titanium implant, EASYMADE TI, marking the first instance of a Korean company achieving this for a customized titanium implant in the U.S. market. Designed for cranial and craniofacial reconstruction, the implant is tailored using individual CT data and produced through advanced 3D printing technology. This clearance is expected to enhance CGBIO's expansion in the U.S. market, responding to the growing demand for personalized reconstruction solutions.

prnewswire

Compugen

Generation Bio

ALPS Medical Breakthrough

Direxion S&P Biotech Bull 3X

VanEck Biotech ETF

Invesco Nasdaq Biotechnology ETF

iShares Biotechnology ETF

Proshares Ultra Nasdaq Biotech

SPDR S&P Biotech

First Trust NYSE Arca Biotech Index Fd

Invesco Biotechnology & Genome ETF

08:00 ETCGBIO Receives FDA 510(k) Clearance for Patient-Specific Titanium Implant 'EASYMADE TI'

CRSP

Crescita Announces Filing and Mailing of Special Meeting Materials and Receipt of Interim Order in respect of Arrangement with ClinActiv Holdings | CRRTF Stock News

CRISPR Therap

Health Care Select Sector SPDR

Ark Innovation ETF

iShares Genomics Immunology and Healthcare ETF

Wisdomtree BioRevolution Fund ETF

VG Health

iShares Global Healthcare

iShares US Pharma

Ark Genomic Revolution ETF

Crescita Announces Filing and Mailing of Special Meeting Materials and Receipt of Interim Order in respect of Arrangement with ClinActiv Holdings | CRRTF Stock News

Crescita Narrows Losses in 2025 and Agrees to Premium All-Cash Takeover by ClinActiv

Crescita Narrows Losses in 2025 and Agrees to Premium All-Cash Takeover by ClinActiv

Crescent Biopharma(CBIO.US)

Crescent Biopharma Announces Grants of Inducement Awards

Crescita Reports First Quarter 2026 Results | CRRTF Stock News

Crescent Biopharma | 10-Q: FY2026 Q1 Revenue: USD 22.52 M

Crescent Biopharma | 8-K: FY2026 Q1 Revenue: USD 22.52 M

Stifel Nicolaus Keeps Their Buy Rating on Crescent Biopharma (CBIO)

08:00 ETCGBIO Receives FDA 510(k) Clearance for Patient-Specific Titanium Implant 'EASYMADE TI'

Crescita Announces Filing and Mailing of Special Meeting Materials and Receipt of Interim Order in respect of Arrangement with ClinActiv Holdings | CRRTF Stock News

Crescita Narrows Losses in 2025 and Agrees to Premium All-Cash Takeover by ClinActiv